Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
Speaker: | Dr. |
|
Format: | Corporate Presentation | |
Date: | ||
Time: | ||
Jefferies Virtual
Speakers: | Dr. |
|
John Vieira, U.S. Head of Commercialization | ||
Format: | Fireside Chat | |
Date: | ||
Time: | ||
A live webcast of the presentations will be available under the “Events and Presentations” in the investors section of the Company’s website at www.sol-gel.com.
About
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:
Chief Financial Officer
+972-8-9313433
Investor Contact:
Solebury Trout
+1-917-312-5998
[email protected]
Source:
Source: Sol-Gel Technologies Ltd.